BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer

Selective inhibition of BET bromodomains

P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.2K citations · Full text

Bet Bromodomains, Genetics, Pathogenesis +3

AmiGO: online access to ontology and annotation data

Seth Carbon, Amelia Ireland, Chris Mungall et al. · Bioinformatics · 2008 · 2K citations · Full text

Ontology (Information Science), Engineering, Genetics +23

Evaluating cell lines as tumour models by comparison of genomic profiles

Silvia Domcke, Rileen Sinha, Douglas A. Levine et al. · Nature Communications · 2013 · 1.4K citations · Full text

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

Wataru Sakai, Elizabeth M. Swisher, Beth Y. Karlan et al. · Nature · 2008 · 1.1K citations · Full text

Cisplatin Resistance, Somatic Variant, Tumor Heterogeneity +10

Resistance to therapy caused by intragenic deletion in BRCA2

Stacey L. Edwards, Rachel Brough, Christopher J. Lord et al. · Nature · 2008 · 979 citations

Intragenic Deletion, Oncogenic Agent, Pathology +4